Standout Papers

Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migr... 2019 2026 2021 2023 256
  1. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial (2019)
    Michel D. Ferrari, Hans‐Christoph Diener et al. The Lancet

Immediate Impact

3 by Nobel laureates 19 from Science/Nature 55 standout
Sub-graph 1 of 24

Citing Papers

Complement in breast milk modifies offspring gut microbiota to promote infant health
2024 Standout
A Monoclonal Antibody to PACAP for Migraine Prevention
2024 Standout
4 intermediate papers

Works of Maja Galić being referenced

Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial
2019 Standout
Secretory antibodies reduce systemic antibody responses against the gastrointestinal commensal flora
2007
and 1 more

Author Peers

Author Last Decade Papers Cites
Maja Galić 334 130 232 26 635
Manuel Ramos-Kuri 92 132 81 19 561
Işıl Fidan 119 63 88 43 546
Mianwang He 487 41 248 28 721
Christine Robinson 102 135 128 25 664
Fatemeh Asgari 129 126 65 41 683
Birgit Keller 68 105 136 42 731
Redda Tekle Haimanot 199 27 106 19 636
Sofia Fernanda Gonçalves Zorzella-Pezavento 25 145 183 43 691
Consuelo Gómez 200 72 132 25 530
Roberto Monreal‐Robles 82 85 34 50 643

All Works

Loading papers...

Rankless by CCL
2026